Novel Platform: AVIDIO
(Artificial Virus for Infectious Diseases and Immuno-Oncology) Patented. Worldwide exclusive rights from Yale University
Farmington, CT, September 5, 2022– CaroGen Corporation (https://carogencorp.com), a developer of trans-formative immunotherapies for cancer and infectious diseases, today announced that Bijan Almassian, PhD, President & CEO, and Timur Yarovinsky, MD, PhD, Vice President of Discovery
We are honored to be working with NIAID/NIH scientists to develop a universal influenza vaccine.
Striving to develop CARG-201 as a novel immunotherapy for potential functional cure of over 250 million patients worldwide chronically infected with hepatitis B virus (HBV). Currently there is no cure for HBV.